Only recently, the endothelin receptor antagonist atrasentan, the sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin and the non-steroidal, selective mineralocorticoid receptor antagonist finerenone, studied in the SONAR, CREDENCE, DAPA-CKD, and the FIDELIO-DKD trials respectively, showed renal and CV protection (Heerspink et al., 2019; Perkovic et al., 2019; Bakris et al., 2020; Heerspink et al., 2020). Here, SLC5A2 is linked to chronic kidney disease.